Compare Illumina, Inc. (ILMN) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Phillips 66 — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while Phillips 66 trades at $278.55 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 2.8× Illumina, Inc.'s market cap, and Phillips 66 pays a 1.8% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Phillips 66 for 62 Days on average.
| ILMN | PSX | |
|---|---|---|
Market Cap | $39.95B | $112.36B |
Volume | 3,169,503 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $293.69 | $281.60 |
52-Week Low | $91.00 | $126.76 |
Typical Hold Time | 83 Days | 62 Days |
Enterprise Value | $41.31B | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
PSX trades at $271.62, up 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $279. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue declined to $132.38B in 2025, but net income improved to $4.40B, and 2026 projections show a rebound to $152.2B revenue and $7.1B net income. The company maintains a solid balance sheet with $72.58B in total assets and recently announced a $1.27 dividend for H2-2026.
The outlook for PSX is positive, supported by structural refining margins and AI-driven operational efficiencies. Investment opportunities include potential price appreciation toward the $279 consensus target and a sustainable dividend. Risks include exposure to volatile oil prices, regulatory changes such as potential diesel export bans, and execution challenges in maintaining profitability amid shifting energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
